Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1459-1464

  Papanikolaou, Xenofon ^a,b,c   Repousis, Panagiotis ^b   Tzenou, Tatiana ^a   Maltezas, Dimitris ^b   Kotsopoulou, Maria ^b   Megalakaki, Katerina ^b   Angelopoulou, Maria ^a   Dimitrakoloulou, Elektra ^a   Koulieris, Efstathios ^a   Bartzis, Vassiliki ^a   Pangalis, Gerasimos ^a   Panayotidis, Panagiotis ^a   Kyrtsonis, Marie Christine ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Clinicallaboratory features; Extramedullary relapse; Multiple myeloma; Overall survival

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PARAPROTEIN; PLATINUM; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; DRUG MEGADOSE; FEMALE; FRACTURE; HUMAN; LABORATORY DIAGNOSIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMACYTOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADULT; AGED; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84879389318     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.746683     Document Type: Article

References (34)

1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002; 94: 2766-2792. (Pubitemid 34478095)
2. D ores G M, L andgren O, M cGlynn K A, et al. P lasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 2009; 144: 86-94.
3. Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007; 92: 143-144. (Pubitemid 46232680)
4. Zeiser R, Deschler B, Bertz H, et al. Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome. Bone Marrow Transplant 2004; 34: 1057-1065. (Pubitemid 40028838)
5. Usmani S Z, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is overrepresented in high risk disease even in era of novel agents. Haematologica 2012;97:1761-1767.
6. Cerny J, Fadare O, Hutchinson L, et al. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol 2008;81:65-69. (Pubitemid 351852757)
7. Billadeau D, Van Ness B, Kimlinger T, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996;88:289-296. (Pubitemid 26230698)
8. Billadeau D, Quam L, Th omas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood 1992;80:1818-1824.
9. Ghobrial I M. Myeloma as a model for the process of metastasis: implications for therapy. Blood 2012; 120: 20-30.
10. A legre A, G randa A, M artinez-Chamorro C, et al. D iff erent patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002; 87: 609-614. (Pubitemid 34640643)
11. Kamble R, Wilson CS, Fassas A, et al. Malignant pleural eff usion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma 2005;46:1137-1142. (Pubitemid 41087017)
12. Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325-330.
13. Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-212. (Pubitemid 351962066)
14. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer 1969;23:167-174.
15. Terpos E, Rezvani K, Basu S, et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005;75:376-383. (Pubitemid 41445076)
16. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793. (Pubitemid 27121271)
17. A vigdor A, R aanani P, L evi I, et al. E xtramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001; 42: 683-687. (Pubitemid 32782776)
18. H ulin C, F acon T, R odon P, et al. E fficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670.
19. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-4053. (Pubitemid 41775908)
20. D ' Amato RJ, Loughnan MS, Flynn E, et al. Th alidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
21. Lu L, Payvandi F, Wu L, et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory eff ects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009; 77: 78-86.
22. Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607-612. (Pubitemid 33134420)
23. L aura R, C ibeira M T, U riburu C, et al. B ortezomib: an eff ective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405-408.
24. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-1867. (Pubitemid 47557312)
25. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140: 625-634. (Pubitemid 351300910)
26. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009; 360: 2645-2654.
27. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
28. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma eff ect: proof of principle. Blood 1996;87:1196-1198. (Pubitemid 26043549)
29. Perez-Simon JA, Sureda A, Fernandez-Aviles F, et al. Reducedintensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006;20:542-545. (Pubitemid 43291766)
30. Au WY, Kwong YL, Lie AK, et al. Extra-medullary relapse of leukemia following allogeneic bone marrow transplantation. Hematol Oncol 1999;17:45-52. (Pubitemid 29502312)
31. Sahara N, Takeshita A, Shigeno K, et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 2002;117:882-885. (Pubitemid 34639251)
32. Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29: 3805-3812.
33. G alani Z, V iniou N, K yrtsonis M C, et al. H epatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission. Anticancer Res 2007; 27: 571-574. (Pubitemid 46374978)
34. Fassas AB, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 2004;45:291-300. (Pubitemid 38181431)